Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

nmbr1stckpckr, You posted an interesting articl

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154090
(Total Views: 548)
Posted On: 02/03/2021 9:28:22 PM
Posted By: Enjay
Re: nmbr1stckpckr #76121
nmbr1stckpckr,

You posted an interesting article from The Guardian which I noticed right before I started to post this one from the UK about new variant.
Link and excerpts follow.

https://www.kcl.ac.uk/news/no-evidence-change...us-variant


No evidence of change in symptoms from new coronavirus variant

First identified in September 2020 in the South East of England, the B.1.1.7 variant has spread rapidly through the UK and elsewhere.

The research study confirms that the new variant is more transmissible, but it does not appear to cause more reinfections or a greater proportion of hospitalisations. Reassuringly, the data from also showed that B.1.1.7 has responded to national lockdown measures, with cases falling significantly even in regions with very high prevalence.

After adjusting the data to account for age and sex, as well as local temperature and humidity, analysis showed that there were no significant differences in the type, number or duration of symptoms between areas with a high prevalence of B.1.1.7 compared with those with a lower prevalence and that this did not change as the new variant spread. There was also no difference in the proportion of reported hospitalisations and reinfections.

The researchers identified 249 likely cases of reinfection during the study period, representing a reinfection rate of 0.7% which is comparable with previous studies of earlier virus variants. This is a positive sign that the immunity built through vaccination against the older variants could also be protective against B.1.1.7.

Finally, the researchers confirmed that the new variant is more easily transmitted than existing virus versions, increasing the R value (a measure of transmissibility) by around a third (35%).


(1)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us